Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25369762 | 1.00 | OPRM1 (0.36) | OPRM1IL4I1HSD17B10MAP4K4CCR1 | |
| SCHEMBL15459351 | 0.94 | OPRM1 (0.35) | OPRM1MAP4K4WDR5 | |
| SCHEMBL15459355 | 0.90 | OPRM1 (0.33) | OPRM1 | |
| SCHEMBL29900378 | 0.83 | OPRM1 (0.36) | OPRM1MAP4K4OPRL1 | |
| SCHEMBL26049063 | 0.83 | HSD17B10 (0.35) | HSD17B10 | |
| SCHEMBL25369707 | 0.83 | OPRM1 (0.36) | OPRM1MAP4K4OPRL1 | |
| SCHEMBL25801653 | 0.82 | OPRM1 (0.44) | OPRM1MAP4K4OPRL1 | |
| SCHEMBL2674905 | 0.80 | WDR5 (0.38) | IL4I1WDR5 | |
| SCHEMBL13809344 | 0.80 | IL4I1 (0.31) | IL4I1WDR5 | |
| SCHEMBL13265691 | 0.80 | OPRM1 (0.37) | OPRM1IL4I1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2022185041-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | OPRM1 2912/4885IL4I1 1991/4885HSD17B10 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.